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Abstract
The 2009 H1N1 influenza pandemic (pH1N1) led to record sales of neuraminidase (NA) inhibitors, which has contributed
significantly to the recent increase in oseltamivir-resistant viruses. Therefore, development and careful evaluation of novel
NA inhibitors is of great interest. Recently, a highly potent NA inhibitor, laninamivir, has been approved for use in Japan.
Laninamivir is effective using a single inhaled dose via its octanoate prodrug (CS-8958) and has been demonstrated to be
effective against oseltamivir-resistant NA in vitro. However, effectiveness of laninamivir octanoate prodrug against
oseltamivir-resistant influenza infection in adults has not been demonstrated. NA is classified into 2 groups based upon
phylogenetic analysis and it is becoming clear that each group has some distinct structural features. Recently, we found that
pH1N1 N1 NA (p09N1) is an atypical group 1 NA with some group 2-like features in its active site (lack of a 150-cavity).
Furthermore, it has been reported that certain oseltamivir-resistant substitutions in the NA active site are group 1 specific. In
order to comprehensively evaluate the effectiveness of laninamivir, we utilized recombinant N5 (typical group 1), p09N1
(atypical group 1) and N2 from the 1957 pandemic H2N2 (p57N2) (typical group 2) to carry out in vitro inhibition assays. We
found that laninamivir and its octanoate prodrug display group specific preferences to different influenza NAs and provide
the structural basis of their specific action based upon their novel complex crystal structures. Our results indicate that
laninamivir and zanamivir are more effective against group 1 NA with a 150-cavity than group 2 NA with no 150-cavity.
Furthermore, we have found that the laninamivir octanoate prodrug has a unique binding mode in p09N1 that is different
from that of group 2 p57N2, but with some similarities to NA-oseltamivir binding, which provides additional insight into
group specific differences of oseltamivir binding and resistance.
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Introduction
The 2009 pandemic swine origin influenza A H1N1 virus
(pH1N1) has reminded the world of the threat of pandemic
influenza [1,2,3]. In 2009, the total sales of Tamiflu (oseltamivir
phosphate) increased to over 3 billion US dollars (Annual General
Meeting of Roche Holding Ltd, 2 March 2010). The total sales of
Relenza (zanamivir) in 2009 were over 1 billion (GlaxoSmithKline
Quarter 4 Report, 4 February 2010). Additionally, 5.65 million
packs of Tamiflu were donated to the WHO in 2009 to replenish
their stockpiles (Roche, Annual General Meeting of Roche
Holding Ltd, 2 March 2010). Since the WHO has downgraded
the threat of pH1N1 from the pandemic level in August 2010,
there have still been ongoing reports of pH1N1 outbreaks in south-
eastern states of the USA, India and New Zealand (US CDC).
Furthermore, a new variant of pH1N1 has even been detected in
Singapore, New Zealand and Australia [4]. Throughout the
world, vaccinations have still been strongly advocated and
stockpiles of oseltamivir and zanamivir are on reserve in case of
another severe influenza outbreak in the near future. Both
oseltamivir and zanamivir are excellent examples of modern
structure-based drug-design and function as competitive inhibitors
of the influenza neuraminidase (NA), and are by far the most
commonly used influenza drugs [5,6,7,8].
Influenza A virus contains two proteins on its surface in addition
to the ion channel M2: hemagglutinin (HA) and NA [9]. Both M2
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M2 drugs are rarely used anymore because M2 develops drug-
resistant mutations very easily [10]. In the influenza virus infection
life cycle, HA binds to terminally linked sialic acid receptors on the
surface of host cells, allowing the virus to gain entry. In order for the
influenza virus to efficiently break free from already infected cells
and to continue replicating, sialic acid containing HA receptors
must be destroyed. NA, which is a sialidase, catalyzes hydrolysis of
terminally linked sialic acid and functions as the receptor-destroying
element of influenza A and B viruses.
Influenza A NA has been grouped into 9 different serotypes,
N1-N9, based upon antigenicity [11]. Additionally, influenza A
NA is further classified into two groups: group 1 (N1, N4, N5 and
N8) and group 2 (N2, N3, N6, N7 and N9), based upon primary
sequence [12]. Group 1 NAs contain a 150-cavity (formed by
amino acids 147–151 of the 150-loop) in their active site, whereas
group 2 NAs lack this cavity [12]. Coordination of the 150-loop
with the 430-loop appears to be critical for the formation of the
150-cavity [13,14]. Soaking experiments of typical group 1 NAs
with inhibitors often result in the closure of the 150-cavity and
indicates some flexibility of the 150-loop [12,15]. Molecular
dynamics simulations also indicate some differences in the
flexibility of the 150-loop between group 1 and group 2 NAs
[14,16]. Structural studies reveal that Asp151 and Arg152 of the
150-loop form key interactions with the 4-group and N-acetyl
group of common NA ligands, respectively. These two residues
move away from the substrate in the open conformation of the
150-loop and closer upon ligand binding [17]. Therefore the 150-
loop plays an essential role in substrate and inhibitor binding [15].
Furthermore, the 150-cavity is currently being successfully
explored as a target for novel NA inhibitors [12,18,19,20].
The design of NA inhibitors is a classic example of structure-
based drug discovery, pioneered by Mark von Itzstein and
colleagues with the advent of the N2, N9 and influenza B NA
structures [5,6,8,21,22,23,24]. Currently there are four NA-
targeting inhibitors that have been approved for use: zanamivir,
oseltamivir, peramivir and laninamivir (laninamivir has recently
been approved in Japan). Additionally, there are many more NA
inhibitors under clinical trials or under vigorous development due
to the public threat of seasonal and pandemic flu and the rise of
drug-resistant viruses [18,19,25,26,27,28]. However, previous
results have indicated that inhibitors which are highly similar to
the natural NA ligand, sialic acid, are less susceptible to the
problem of drug-resistance [29,30,31]. This suggests that drugs
like zanamivir, that are similar to sialic acid and its transition state
analogue 2-deoxy-2,3-dehydro-N-acetylneuraminic acid (Neu5A-
c2en or DANA), have an advantage over oseltamivir, which is less
similar (Figure 1). However, zanamivir must be administered twice
daily over 5 consecutive days to attain its maximum effect.
Therefore, the development of novel inhibitors that possess long
term efficacy and that are also effective against oseltamivir-
resistant influenza viruses is in great demand.
Laninamivir (R-125489) is a very promising, novel influenza
NA inhibitor with high potency and the ability to efficiently inhibit
common oseltamivir-resistant viruses, including those with the
ubiquitous His274Tyr substitution [32,33,34]. Recently, lanina-
mivir and its prodrug, laninamivir octanoate (CS-8958) have been
approved for use in Japan as Inavir (Daiichi Sanko Press Release,
10 Sept. 2010). Clinical studies have confirmed that the prodrug,
laninamivir octanoate, is effective in both children and adults,
however laninamivir octanoate has not yet been demonstrated to
be more effective than oseltamivir against oseltamivir-resistant
His274Tyr H1N1 infection in adult patients [35,36,37]. Like
zanamivir, the core structure of laninamivir is Neu5Ac2en, the NA
transition state analogue (Figure 1). Both laninamivir and
zanamivir contain a 4-guanidino group that is not present in
Neu5Ac2en and laninamivir also contains an additional 7-
methoxy group (Figure 1). Laninamivir octanoate is the octanoyl
prodrug of laninamivir (Figure 1). In a similar manner that
oseltamivir is processed to oseltamivir carboxylate in the liver, it
has been demonstrated that laninamivir octanoate is processed to
laninamivir in the lung [33]. The laninamivir 7-methoxy and its
prodrug octanoyl ester increase the ability to be retained in the
lungs and to function effectively in a single inhaled dose
[32,33,34,37,38]. Moreover, the high similarity of laninamivir to
the NA transition state analogue, Neu5Ac2en, allows for an
effective response against oseltamivir-resistant NA [32,33,34,35].
For these reasons, laninamivir and laninamivir octanoate offer
advantages over both oseltamivir and zanamivir.
In order to comprehensively assess the effectiveness of the novel
NA inhibitors, laninamivir and laninamivir octanoate, in compar-
ison to oseltamivir and zanamivir, and to reveal the structural basis
of their inhibition, we utilized: 1) pandemic A/RI/5+/1957 H2N2
N2 (p57N2) as a typical group 2 NA, 2) p09N1 as an atypical
group 1 NA, and 3) avian H12N5 NA (N5) as a typical group 1
NA. Soluble, active p57N2, p09N1 and N5 were expressed in a
baculovirus expression system and purified based upon previously
reported methods [13,39,40]. NA inhibition assays were carried
out and complex crystal structures were solved for laninamivir,
laninamivir octanoate, zanamivir and oseltamivir in order to
elucidate the structural basis of their inhibition. Our results
indicate that laninamivir is potent against all 3 NAs with a similar
binding mode to zanamivir. Laninamivir and zanamivir were
more effective against group 1 N5, with a 150-cavity, than atypical
group 1 p09N1 and group 2 p57N2, with no 150-cavity. This
indicates that the ability of the bulky 4-guanidino group of
zanamivir and laninamivir to become buried deep beneath the
150-loop is an important factor for their group-specific binding
and inhibition. Furthermore, we confirm the binding of the
prodrug, laninamivir octanoate, to p57N2, with a similar binding
mode to laninamivir. Surprisingly, the p09N1-laninamivir octa-
noate complex shows a completely different binding mode: p09N1
Author Summary
The influenza neuraminidase (NA) enzyme is the most
successful drug target against the seasonal and pandemic
flu. The 2009 H1N1 flu pandemic led to record sales of the
NA inhibitors oseltamivir (Tamiflu) and zanamivir (Relenza).
Recently, a new drug, laninamivir (Inavir), has been
approved for use in Japan can also be administered
effectively using a single dose via its octanoate prodrug
(CS-8958), however its effectiveness against oseltamivir-
resistant influenza infection has not been demonstrated in
clinical studies. In this study we comprehensively evaluate
the effectiveness of laninamivir and its prodrug using NA
from different groups with different active site features.
We expressed and purified a group 2 NA from the 1957
pandemic H2N2, an atypical group 1 NA from the 2009
H1N1 pandemic and a group 1 NA from avian H12N5. NA
inhibition was assayed and NAs were further crystallized
with each inhibitor to determine the structural basis of
their action. We found that laninamivir inhibition is highly
potent for each NA, however binding and inhibition of
laninamivir and its prodrug showed group specific
preferences. Our results provide the structural and
functional basis of NA inhibition using classical and novel
inhibitors, with NAs from multiple serotypes with different
properties.
Laninamivir-NA Group Specific Mechanisms
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complex, forming a hydrophobic pocket that is also necessary to
accommodate oseltamivir. The observation of different Glu276
rotation in p09N1 and p57N2 offers insight into the group specific
differences of oseltamivir binding and resistance.
Results
Comparison of the active sites of p57N2, p09N1 and N5
In our previous studies, we have successfully obtained both
soluble p09N1 and N5 using a baculovirus expression system
originally developed by Xu et al. [13,15,39]. To determine the
functional and structural basis of NA inhibition and binding by
laninamivir and its prodrug, we first expressed and purified a new
group 2 member from the 1957 pandemic H2N2 virus, p57N2,
using similar methods. In this way, three major types of known
NAs are covered in this comprehensive analysis: typical group 2
p57N2, atypical group 1 p09N1 and typical group 1 N5.
p57N2 was crystallized and its structure was solved by molecular
replacement using A/TOKYO/3/1967 (H2N2) N2 (PDB code:
1IVG) as a search model [41]. As expected, the active site of p57N2
is highly similar to other group 2 NAs in that it has no 150-cavity
(Figure 2 - upper left). Like the available group 2 A/TOKYO/3/
1967 (H2N2) N2 and A/Memphis/31/98 (H3N2) N2 structures
[42,43], p57N2 also contains a 150-cavity deficient active site with a
salt bridge between Asp147 and His150, confirming the presence of
a stable, closed 150-loop (Figure 2 - upper left; Figure 3A).
Although the atypical group 1 p09N1 also has a 150-cavity deficient
active site (Figure 2 - upper right), the 150-loop is quite different from
that of p57N2. The p09N1 150-loop sequence (residues 147–150) is
GTIKD, however p57N2 contains DTVHDw i t h3p o l y m o r p h i c
amino acids. The p09N1 therefore contains no Asp147-His150 salt
bridge, but instead contains Ile149, which is commonly found in group
2 NAs, and Ile149 is able to rest closer to the hydrophobic Pro431 than
Val149 is [13]. N5 on the other hand contains Val149 with no 147–
150 salt bridge and displays a 150-cavity like all other structure-known
NAs with Val149 and no 147–150 salt bridge (Figure 2 - lower left)
[15]. Therefore, NAs with the three major styles of the 150-loop are
covered in our comparative analysis.
Differential inhibition of N5, p09N1 and p57N2 by
oseltamivir, zanamivir, laninamivir and laninamivir
octanoate
All NA proteins produced in the baculovirus expression system
displayed stable sialidase activity. IC50 values and 95% confidence
intervals (CIs) are given in Table 1. Oseltamivir inhibited the
activity of N5, p09N1 and p57N2 with IC50 values of 0.83 nM,
0.54 nM and 0.79 nM, respectively. Laninamivir inhibition was
best for group 1 N5, followed by atypical group 1 p09N1 and
worst for group 2 p57N2. Zanamivir was also more effective
against N5 than p09N1 and p57N2, however the difference of
zanamivir inhibition between p09N1 and p57N2 is not statistically
significant (Table 1). Zanamivir inhibited N5, p09N1 and p57N2
with IC50 values of 0.59 nM, 1.11 nM and 1.36 nM, respectively.
Laninamivir was in a similar range with zanamivir for N5, p09N1
and p57N2 with IC50 values of 0.90 nM, 1.83 nM and 3.12 nM,
respectively. However inhibition of laninamivir was 1.53, 1.65 and
2.29 fold lower than zanamivir for N5, p09N1 and p57N2,
respectively. Inhibition of N5, p09N1 and p57N2 by laninamivir
octanoate was not as efficient, with IC50 values of 389 nM,
947 nM, and 129 nM, respectively. Hence inhibition of p57N2 by
laninamivir octanoate was much better than for p09N1.
Group specific NA binding of laninamivir and zanamivir
To determine the structural basis of the inhibition of
laninamivir relative to zanamivir, we solved the very first complex
structures of laninamivir with p57N2, p09N1 and N5 at
Figure 1. The chemical structures of influenza NA inhibitors used in this study. 1, Neu5Ac2en (NA transition state analogue); 2, zanamivir;
3, laninamivir; 4, laninamivir octanoate (CS-8958); and 5, oseltamivir.
doi:10.1371/journal.ppat.1002249.g001
Laninamivir-NA Group Specific Mechanisms
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complex structures of zanamivir with p57N2, p09N1 and N5 at
1.9 A ˚, 1.9 A ˚ and 1.6 A ˚, respectively [15]. Like zanamivir, the
binding mode of laninamivir to all 3 NAs is highly similar to that of
the NA transition state analogue, Neu5Ac2en. Some minor
differences in the NA-inhibitor interactions between laninamivir
and zanamivir are observed within each of the 3 NAs due to the
additional hydrophobic 7-methoxy group of laninamivir; however
all of the laninamivir complex structures highly resemble
zanamivir binding (Table 2, Figure 3).
Figure 2. Comparison of the active sites of p57N2, p09N1 and N5. Group 2 p57N2 has a 150-cavity deficient active site with a salt bridge
between Asp147 and His150 which stabilizes the closed conformation of its 150-loop (upper left - green). p09N1 is an atypical group 1 structure and
also has a 150-cavity deficient active site similar to many group 2 structures (upper right - magenta). N5 is a typical group 1 NA and displays a 150-
cavity in its uncomplexed structure (lower left - yellow) that closes upon inhibitor binding (lower right - yellow: N5-laninamivir complex).
doi:10.1371/journal.ppat.1002249.g002
Figure 3. Binding of laninamivir and zanamivir to p57N2, p09N1 and N5. In each panel, zanamivir appears as the same color as the
respective NA active site and laninamivir appears as turquoise. Acidic and basic side chains of key residues are colored red and blue, respectively. The
4-guanidino group of laninamivir and zanamivir is buried deep beneath the 150-loop where it engages many key interactions with NA residues
(Table 2). Although the binding modes of laninamivir and zanamivir are highly similar, the accessibility of the 4-guanidino to its binding site is lowest
in p57N2, with a 147–150 salt bridge in its closed 150-loop (A - green) and highest in group 1 N5, which contains a 150-cavity in its uncomplexed
structure (C - yellow). Inhibition by zanamivir and laninamivir are highest for N5, and lowest for p57N2. p09N1, with its unique 150-loop
characteristics (B - magenta), has intermediate laninamivir inhibition.
doi:10.1371/journal.ppat.1002249.g003
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we first carried out a detailed analysis of interactions with the 150-
loop in each inhibitor complex. In all of the zanamivir and
laninamivir structures, the 4-guanidino group is buried deep
beneath the 150-loop where it forms many key hydrogen bonds
with Glu119, the Trp178 peptide carbonyl, Glu227, and the
Asp151 side chain and peptide carbonyl (Figure 3, Table 2). This
4-guanidino group is the most buried part of the inhibitor in the
structure (Figure 3), which is emphasized by the absence of any
water molecules beneath the 150-loop and surrounding the 4-
guanidino group. Although the 4-guanidino plays an essential role
for the high affinity of laninamivir and zanamivir to NA,
accessibility of the 4-guanidino to its binding site deep below the
150-loop is a crucial factor for the laninamivir and zanamivir
binding process. The typical group 1 N5 contains a 150-cavity in
its uncomplexed structure and inhibition of N5 by laninamivir and
zanamivir was better than inhibition of p09N1 and p57N2, which
contain no 150-cavity in their uncomplexed structures (Figure 3,
Table 1). Therefore, our data indicate that the group specific
accessibility of the laninamivir and zanamivir 4-guanidino to the
NA active site is a key factor in determining their effectiveness.
Slight differences in the interactions between the binding of
laninamivir and zanamivir were observed due to the additional
laninamivir 7-methoxy group (Table 2). Although this laninamivir
7-methoxy group is oriented away from its own ring oxygen and is
pointed toward the hydrophobic Ile222 side chain, its distance is
relative far at over 5 A ˚. Interactions between Arg371 and the
inhibitor carboxylate were always highly consistent; however the
carboxylate-Arg118 interactions are closer in zanamivir than
laninamivir in every NA complex (Table 2). On the other hand,
the carboxylate-Arg292 interactions are further in zanamivir than
laninamivir in every NA complex (Table 2). Unlike p09N1 and
p57N2, N5 contains Tyr347, which forms an additional hydrogen
bond with the carboxylate of each inhibitor (Figure 3C).
Differential binding of the octanoate prodrug to p57N2
and p09N1 via enhanced p09N1 Glu276 rotation
Laninamivir octanoate complex structures with p09N1 and
p57N2 (Figure 4) were solved at 1.6 A ˚ and 2.2 A ˚, respectively,
demonstrating that the laninamivir octanoate prodrug can also
directly inhibit NA without further processing. In p57N2,
Table 2. Comparison of key NA-ligand interactions.
p57N2 Distance p09N1 Distance N5 Distance
Protein
Group Ligand Group zanamivir laninamivir CS-8958 zanamivir laninamivir CS-8958 zanamivir laninamivir
R118 carboxy 2.83/3.14 2.87/3.28 2.96/3.42 2.76/3.46 2.75/3.60 2.83/3.64 2.81/3.51 2.77/3.62
E119 4-X 3.33/3.64 3.26/3.76 3.20/4.03 3.22/3.77 3.24/3.93 3.28/3.88 3.30/3.94 3.27/3.90
D151* 4-X 2.94 2.90 3.00 2.96 2.89 2.92 2.91 2.79
D151** 4-guan 3.15 2.95 2.93 3.01 2.88 2.96 2.93 2.91
R152 5-Ac 2.87 2.84 2.86 2.86 2.82 2.82 2.83 2.88
W178** 4-guan 2.71/3.07 2.68/3.00 2.86/2.99 2.73/3.11 2.69/2.95 2.79/3.16 2.82/3.18 2.76/3.17
R224dN 9-O 3.37 3.41 3.09 3.33 3.45 - 3.43 3.24
R224dN 9-ester*** - - 3.52 - - - - -
E227 4-guan 3.03 3.09 3.48 3.12 3.06 3.04 3.02 3.02
S247 9-ester-O - - - - - 3.50 - -
E276 8-OH 2.80 2.76 2.71 2.72 2.63 - 2.65 2.68
E276 9-O 2.65 2.61 2.80 2.59 2.61 - 2.52 2.59
R292 carboxy 3.36/3.43 3.27/3.29 3.26/3.49 3.19/3.24 3.09/3.16 3.14/3.12 3.14/3.19 3.09/3.11
R292 8-OH 3.52/3.52 3.50/3.62 3.56/3.73 3.43/3.73 3.58/3.82 3.46/3.48 3.64/3.89 3.56/3.71
N294 9-ester-O - - - - - 2.64,3.93 - -
R371 carboxy 2.71/2.79 2.76/2.77 2.43/2.81 2.70/2.94 2.67/2.83 2.80/2.95 2.89/2.93 2.74/2.80
Y406 ring-O 3.00 3.14 2.96 3.14 3.15 3.36 3.25 3.03
All residues are N2 numbered and distances are given in A ˚. The 4-guanidino group of zanamivir, laninamivir and CS-8958 is abbreviated as ‘4-guan’. Bond distances are
based on the distances between oxygen and nitrogen atoms and do not include hydrogen atoms, which cannot be directly observed using X-ray diffraction. Distances
are given for molecule A in the asymmetric unit of each structure and are highly consistent between molecules. The distance of the unique hydrogen bond between the
laninamivir octanoate 9-ester-O and p09N1 Asn294 is given for both molecules A and B as it varies significantly. Laninamivir octanoate is listed as CS-8958 to save space.
*The Asp151 side chain carboxy hydrogen bonds with the 4-N of all the ligands used in this study.
**The Asp151 and Trp178 backbone carbonyl groups both hydrogen bond with the 4-guanidino group of zanamivir, laninamivir and laninamivir octanoate.
***The laninamivir octanoate 9-ester-carbonyl forms a hydrogen bond with N2 Arg224.
doi:10.1371/journal.ppat.1002249.t002
Table 1. IC50 values and 95% CIs for the inhibition of p57N2,
09N1 and N5.
p57N2 p09N1 N5
IC50 95% CI IC50 95% CI IC50 95% CI
oseltamivir 0.79 0.64 - 0.98 0.54 0.38 - 0.78 0.83 0.62 - 1.10
zanamivir 1.36 1.11 - 1.66 1.11 0.74 - 1.66 0.59 0.40 - 0.86
laninamivir 3.12 2.39 - 4.09 1.83 1.46 - 2.29 0.90 0.64 - 1.28
CS-8958 129 98 - 171 947 751 - 1192 389 329 - 459
Laninamivir octanoate is listed as CS-8958 to save space.
doi:10.1371/journal.ppat.1002249.t001
Laninamivir-NA Group Specific Mechanisms
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with an additional, novel hydrogen bond between the 9-ester
carbonyl and Arg224 (Figure 4A). p09N1, on the other hand, has a
totally different binding mode where the prodrug’s ester is oriented
toward Asn294 rather than Arg224 (Figure 4B). p09N1 Glu276 is
also in a different orientation in the laninamivir octanoate complex
structure than in the zanamivir or laninamivir complex structures
and forms a salt bridge with Arg224 in the same manner as
oseltamivir binding (Figure 4 and 5). The rotation of p09N1
Glu276 places it out of range for hydrogen bonding with the 8-OH
and 9-ester-O of laninamivir octanoate. Instead, the p09N1-
laninamivir octanoate 9-ester-O forms a unique hydrogen bond
with Asn294 (Figure 4B). Additionally, 09N1 Ser247 forms
another hydrogen bond with the laninamivir octanoate 9-ester-
O at 3.4–3.5 A ˚. Still, the Glu276 rotation results in less hydrogen
bonding in the p09N1-laninamivir octanoate complex compared
to p57N2 (Figure 4C, Table 2).
In both structures, there is no observed electron density
corresponding to the octanoyl carbon chain indicating that this
part of the molecule is highly flexible and does not engage many
stable hydrophobic interactions with p09N1 or p57N2. Still,
electron density surrounding the entire ester can be observed in
both complex structures. Furthermore, in p09N1, the position 7-
methoxy of laninamivir octanoate is also oriented slightly away
from its N-acetyl group relative to laninamivir and there is
additional electron density pointing toward the ring, indicating
lower stability of the p09N1-laninamivir octanoate complex
(Figure 4). In all of our NA complex structures, bond distances
in each molecule of the asymmetric units are very similar, however
in the p09N1-laninamivir octanoate structure some greater
differences are observed between molecule A and B in the
asymmetric unit, which further reflects the lower stability of the
prodrug’s octanoyl ester in p09N1. In p09N1 molecule A, the
distance between the 9-ester-O and Asn294 is 2.64 A ˚, however in
molecule B the distance is much further at 3.93 A ˚ (Table 2).
An oseltamivir-like binding mode of laninamivir
octanoate with p09N1
To our surprise, the binding mode of the p09N1-laninamivir
octanoate complex structure is similar to all known NA-oseltamivir
complex structures with respect to the Glu276-Arg224 interactions.
Therefore, we also solved the p09N1 oseltamivir complex structure
at a resolution of 1.7 A ˚. As observed in the other available
oseltamivir-NA complex structures, in the p09N1-laninamivir
octanoate complex structure, Glu276 indeed forms a salt bridge
with Arg224, creating a hydrophobic pocket which accommodates
Figure 4. Binding of the laninamivir octanoate prodrug (CS-8958) to p57N2 and p09N1. A) Binding of laninamivir octanoate to p57N2,
which is similar to laninamivir/zanamivir NA binding, except with a novel hydrogen bond between the 9-ester carbonyl and Arg224. B) Unique
binding mode of laninamivir octanoate to p09N1. Glu276 is rotated to form a salt bridge with Arg224 and there is a novel hydrogen bond between
the laninamivir octanoate 9-ester-O and Asn294. C) Comparison of laninamivir octanoate binding to p57N2 and p09N1. Key residues are labeled.
Tyr252 is group 1 specific and takes part in a hydrogen bond network with His274 and Glu276. The less bulky Thr252 (compared to group 1 Tyr252) is
group 2 specific and allows for greater movement of residue 274 away from Glu276. The His274Tyr substitution results in group 1 specific oseltamivir-
resistance also via Glu276 interactions.
doi:10.1371/journal.ppat.1002249.g004
Figure 5. Comparison of oseltamivir (yellow), laninamivir
octanoate (magenta) and laninamivir (turquoise) binding to
p09N1. Laninamivir binds to p09N1 with a similar active site
conformation to the uncomplexed structure. Both laninamivir octano-
ate and oseltamivir binding to p09N1 induces rotation of Glu276
toward Arg224 where they form a salt bridge. This Glu276 rotation
creates a hydrophobic pocket that accommodates the hydrophobic
pentyl ether side chain of oseltamivir, however results in a weaker
overall binding mode of laninamivir octanoate. The terminal carbon of
the oseltamivir side chain is 3.73 A ˚ from the hydrophobic Glu276 Cb.
doi:10.1371/journal.ppat.1002249.g005
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[7,29,44,45].Thishydrophobicsidechainofoseltamivirisfavorably
parallel to the Cb and Cc of Glu276 on one end and at the other
end is pointed toward the hydrophobic Ile222 side chain, which
contributes significantly to the high level of oseltamivir inhibition.
Discussion
Recent studies have demonstrated that the novel influenza A
virus NA inhibitors, laninamivir and laninamivir octanoate, are
highly effective and have some advantages over zanamivir and
oseltamivir [33,34,35,37,38]. In this study we verify that
laninamivir, which highly resembles the NA transition state
analogue, Neu5Ac2en, is indeed effective at inhibiting highly
purified p57N2, p09N1 and N5, representing the three major
types of all structure-known NAs with distinct 150-loop properties.
Zanamivir and laninamivir are clearly more similar to sialic acid
and Neu5Ac2en, than oseltamivir, which renders zanamivir and
laninamivir less susceptible to drug-resistance and effective against
many oseltamivir-resistant viruses [29,30,31]. The high degree of
similarity between the binding modes of zanamivir and laninamivirin
all of the NA complex structures indicates that zanamivir and
laninamivir should be effective against the same drug-resistant
mutations. However, laninamivir contains an additional 7-methoxy
group which is oriented toward Ile222. Although the distance
between the laninamivir 7-methoxy and Ile222 is relative far (over
5A ˚), laninamivir may be susceptible to Ile222Arg, a rare drug-
resistant substitution [46]. Moreover,the additional 7-methoxy group
of laninamivir may disrupt hydrogen bonding of the 7-O with water
and likely contributes to a slightly lower inhibition of laninamivir
comparedtozanamivirthatwasobservedforall3NAshere(Table1).
Although zanamivir and laninamivir are highly similar to
Neu5Ac2en, they both contain an artificial bulky 4-guanidino
group. Upon binding, this 4-guanidino group becomes buried
deep beneath Asp151 of the closed 150-loop and forms many
hydrogen bonds which contribute to the high affinity of zanamivir
and laninamivir to NA. However, the bulky 4-guanidino must be
able to clear the 150-loop in order to bind NA and therefore a
closed 150-loop may hinder the entry of zanamivir and
laninamivir into the NA active site. In the open state of the 150-
loop, when the 150-cavity is formed, Asp151 shifts over 1.5 A ˚ (the
Asp151 Cc is shifted over 2 A ˚ in N5) away from the ligand binding
site, which should facilitate entry of inhibitors like zanamivir and
laninamivir [12,15,17]. A similar model has recently been
proposed by Wang et al., however this was based on a computer
simulation using only the group 1 H5N1 NA structure [47].
The group specific 150-loop accessibility, based upon our
structures of p57N2, p09N1, and N5, is consistent with the
inhibition efficiency of laninamivir and zanamivir. Group 2 p57N2
contains an Asp147-His150 salt bridge, limiting the flexibility of its
closed 150-loop and inhibition of p57N2 by laninamivir was the
lowest (Figure 3A). p09N1 is an atypical group 1 with no 150-cavity,
but no Asp147-His150 salt bridge, and inhibition of p09N1 by
laninamivir was better than p57N2 (Figure 3B). The typical group 1
N5 contains a 150-cavity in its uncomplexed structure and
inhibition of N5 by both laninamivir and zanamivir was the highest
(Figure 3C). Therefore, we provide structural and functional
evidence that the open 150-loop of a typical group 1 NA may
facilitate the entry of the 4-guanidino group of zanamivir and
laninamivir into the NA active site, relative to the closed 150-loop of
group 2 NAs. The additional hydrogen bond between Tyr347 and
the inhibitor carboxylate is also a key factor in explaining the higher
N5 inhibition relative to p09N1 and p57N2. However, like the
closed 150-loop, this residue also makes the active site cavity smaller
and in this way may also limit access of inhibitors to the N5 active
site. Furthermore, this residue is found only in group 1 NAs which
contain an open 150-loop cavity [12]. Thus, Tyr347 may
compensate for the open 150-loop in regards to substrate binding.
The complex structure of p57N2 with the laninamivir octanoate
prodrug has a similar binding mode to laninamivir and zanamivir,
however laninamivir octanoate in complex with p09N1 is
completely different. This is the first time, as far as we know, that
the same inhibitor has been observed to bind in two completely
different conformations to influenza NAs. Additionally, p57N2
Arg224 forms a unique hydrogen bond with the laninamivir
octanoate 9-ester carbonyl, and p09N1 Asn294 and Ser247 form
unique hydrogen bonds with the laninamivir octanoate 9-ester-O.
However, the novel conformation of the laninamivir octanoate-
p09N1 complex disrupts any hydrogen bonding with Glu276. The
overall lack of hydrogen bonds and instability in the p09N1-
laninamivir octanoate structure relative to p57N2 provides the
structural basis for higher laninamivir octanoate inhibition of
p57N2 observed in our study and a previous report demonstrating
better laninamivir octanoate inhibition of H2N2 and H3N2 viruses
over H1N1 viruses [34]. The absence of any electron density
surrounding the octanoyl carbon chain of laninamivir octanoate
indicates that it is unable to take part in any favorable interactions
with p57N2 and p09N1. The disordered octanoyl carbon chain
likely destabilizes the interactions between the NA active site and
the laninamivir octanoate 8-OH and 9-ester, which is indicated by
the lower electron density surrounding the 9-ester. Therefore, the
lower inhibition efficiency of laninamivir octanoate relative to
laninamivir is not surprising.
Binding of oseltamivir to p09N1 was indeed highly similar to the
binding observed in previous reports and is also similar to the
binding mode of laninamivir octanoate to p09N1. Oseltamivir
contains a 4-amino group, instead of the 4-guanidino group found
in zanamivir and laninamivir, and is actually more similar to the
natural ligand in this regard. Therefore, the orientation of the 150-
loop during oseltamivir binding is not a major factor. Instead, the
binding preference of oseltamivir for p09N1 over p57N2 and N5
may be instead explained by the ability of Glu276 to adopt the
conformation that is critical to accommodate the osetalmivir
pentyl ether side chain, which replaces the glycerol moiety of
zanamivir, laninamivir and sialic acid. The observation that this
Glu276 conformation occurs in the p09N1-laninamivir octanoate
complex, but not the p57N2-laninamivir octanoate complex may
indicate that this conformation is more stable in p09N1 after
ligand binding which may explain why inhibition of p09N1 by
oseltamivir was the best relative to N5 and p57N2.
In addition, this observation of different Glu276 dynamics in
group 1 p09N1 compared to group 2 p57N2 offers some new
insights into the group specificity of the oseltamivir-resistant
His274Tyr substitution. The His274Tyr mutation is easily selected
for N1 viruses, however cannot be selected for N2 virus types as
N2 His274Tyr binding to oseltamivir is not impaired [48]. In
group 2 NAs, Tyr274 is able to move away from Glu276 due to a
small neighboring Thr252 residue, and oseltamivir can still bind
for His274Tyr [30]. The native His274 is also further away from
Glu276 in our p57N2-laninamivir octanoate structure and does
not hydrogen bond with it. In group 1 NA, Tyr274 is not able to
move away from Glu276 because of the bulky neighboring Tyr252
side chain, which prevents it from accommodating oseltamivir
[30]. In a similar manner, the group 1 Tyr252 side chain promotes
the native His274 to occupy a position where it can participate in a
hydrogen bond network with Glu276 and Arg224 as observed in
our 09N1-laninamivir octanoate structure (Figure 4C).
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is not significantly better than oseltamivir against oseltamivir-
resistant His274Tyr H1N1 infection in adult patients [36]. Since
the laninamivir octanoate prodrug binds to p09N1 in a similar
manner to oseltamivir, this may offer some explanation as to why
laninamivir octanoate has a similar effect as oseltamivir against
His274Tyr H1N1. However, this may indicate that the laninami-
vir octanoate is not processed, or processed slowly, to laninamivir
in the adult patients from this study, since laninamivir has been
clearly demonstrated to be effective against the oseltamivir-
resistant His274Tyr influenza A viruses [32,33,34]. Further
investigation into the efficacy of laninamivir octanoate in adults
in clearly needed.
The results from this comprehensive analysis of group 2 p57N2,
atypical group 1 p09N1 and typical group 1 N5 support the
hypothesis that influenza NA inhibitors which more closely
resemble the NA transition state analogue, Neu5Ac2en, are more
likely to remain effective against NAs from both groups and with
various drug-resistant amino acid substitutions. Most importantly,
we provide mechanisms to explain the group 1 preference of
laninamivir and zanamivir and the differential binding of the
octanoate prodrug to group 1 p09N1 and group 2 p57N2 derived
from pandemic influenza viruses.
Materials and Methods
Reagents
Methylumbelliferyl-N-acetylneuraminic acid (MUNANA) was
purchased from J&K Scientific Ltd. Sialic acid (Neu5Ac) was
purchased from Sigma (Cat. No. 855650) and used without further
purification. Laninamivir, laninamivir octanoate, zanamivir and
oseltamivir were readily synthesized according to the relevant
literatures [49,50,51,52,53]. All products were characterized by
their NMR or MS spectra.
Table 3. Crystallographic X-ray diffraction and refinement statistics.
N2-
zanamivir
N2-
lanamivir
N2-
CS-8958
09N1-
zanamivir
09N1-
laninamivir
09N1-
CS-8958
09N1-
oseltamivir
N5-
lanamivir
Data collection
Space group P21 P21 P21 C2221 C2221 C2221 C2221 P4
Cell dimensions
a, b, c (A ˚) 90.13 89.93 90.45 118.45 118.26 118.67 118.24 112.56
140.00 140.31 140.18 90.30 136.96 137.09 137.10 137.16 112.56
90.17 89.89 118.47 118.48 118.57 118.65 66.81
a, b, c (u) 90, 101.3, 90 90,101.5,90 90, 101.2, 90 90, 90, 90 90, 90, 90 90, 90, 90 90, 90, 90 90, 90, 90
Resolution (A ˚) 50-1.90
(1.97-1.90)
50-1.80
(1.86-1.80)
50-2.20
(2.28-2.20)
50-1.90
(1.97-1.90)
50-1.80
(1.86-1.80)
50-1.60
(1.66-1.60)
50-1.70
(1.76-1.70)
50-1.60
(1.66-1.60)
Rmerge 0.120 (0.396) 0.126 (0.551) 0.162 (0.491) 0.155 (0.443) 0.147 (0.531) 0.103 (0.317) 0.135 (0.519) 0.082 (0.554)
I/sI 11.0 (2.1) 12.7 (3.0) 9.6 (3.3) 12.8 (4.7) 16.5 (3.6) 20.6 (6.2) 17.1 (4.0) 22.1 (2.8)
Completeness (%) 98.7 (90.0) 99.9 (99.9) 99.9 (99.9) 99.4 (99.6) 99.9 (99.7) 99.6 (99.0) 100.0 (100.0) 100.0 (100.0)
Redundancy 4.1 (3.6) 4.1 (4.1) 3.9 (4.0) 6.5 (5.5) 10.6 (9.6) 7.1 (6.8) 8.1 (7.0) 6.1 (5.8)
Refinement
Resolution (A ˚) 41.27-1.89 42.99-1.80 43.17-2.20 36.13-1.90 34.60-1.80 25.90-1.60 30.00-1.69 37.80-1.60
No. reflections 160592 190839 103790 71738 86190 122842 103720 105988
Rwork/Rfree 0.1531/0.1838 0.1516/0.1698 0.1548/0.1910 0.1673/0.1933 0.1938/0.2135 0.1400/0.1767 0.1387/0.1833 0.1268/0.1606
No. atoms
Protein 12380 12380 12397 6175 6098 6114 6098 6194
Ligand/ion 96 100 108 51 53 57 45 50
Water 2154 1934 1394 765 1301 1278 802 1162
B-factors
Protein 15.2 13.4 14.3 11.9 9.9 8.2 9.9 14.1
Ligand/ion 12.9 9.5 12.7 13.2 9.6 9.9 10.5 10.5
Water 31.8 31.2 28.4 29.7 26.7 31.4 29.8 33.7
R.m.s. deviations
Bond lengths (A ˚) 0.005 0.006 0.006 0.003 0.004 0.004 0.003 0.004
Bond angles (u) 1.030 1.127 0.984 0.840 0.935 1.069 0.842 1.008
Ramachandran plot
Most favored (%) 85.7 86.1 84.9 85.2 84.7 85.5 85.3 87.7
Additionally favored (%) 13.6 13.1 14.2 14.5 15.0 13.9 14.4 11.9
Generally allowed (%) 0.8 0.8 0.8 0.3 0.3 0.6 0.3 0.4
Disallowed (%) 0 0 0 00000
Laninamivir octanoate is listed as CS-8958 to save space.
doi:10.1371/journal.ppat.1002249.t003
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NA was prepared in a baculovirus expression system accordingto
methods based on an original method reported by Xu et al. [39].
Both N5 and p09N1 were prepared as previously described in our
laboratory [13,15]. For p57N2, the cDNA encoding amino acid
residues 83–469 were recombined into the baculovirus transfer
vector pFastBac1(Invitrogen), with a GP67 signal peptide, a 6X his-
tag, a tetramerizing sequence and a thrombin cleavage site at the N-
terminus. Recombinant baculovirus was prepared based on the
manufacturer’s protocol (Invitrogen). Sf9 suspension cultures were
grown in Sf-900 II SFM serum-free media (GIBCO) at 28uCa n d
120 RPM and transfected with high-titer recombinant baculovirus.
After growth of the transfected Sf9 suspension cultures for 3 days,
centrifuged media were applied to a HisTrap FF 5 mL column (GE
Health)which waswashedwith20–50 mMimidazole,and then NA
was eluted using 200–300 mM imidazole. After dialysis, thrombin
digestion (Sigma, 3 U/mg NA; overnight at 4uC) and gel filtration
chromatography using a Superdex-200 10/300 GL column (GE
Healthcare), NA fractions were analyzed by SDS-PAGE. High-
purity NA fractions were pooled and concentrated using a
membrane concentrator with a molecular weight cutoff of 10 kD
(Millipore). A buffer of 20 mM Tris-HCl, 50 mM NaCl, pH 8.0
was used for gel filtration and protein concentration.
Competition experiments
A neuraminidase inhibition assay using MUNANA was per-
formed as described by Potier et al. with modifications [54]. Briefly,
10 uL of purified, recombinant NA (10 nM) was mixed with 10 uL
ofinhibitorand incubated for30 minatroomtemperature.NAand
inhibitors were carefully diluted in fresh PBS buffer. At least 5
concentrations of each inhibitor at an appropriate range were used
for each repeat. Following incubation, 30 uL of 166 uM MU-
NANA in 33 mM MES and 4 mM CaCl2 (pH 6.0) was added to
the solution to start the reaction using a 12-tip pipette (Eppendorf).
Apositiveand anegativecontrolwereincludedineach12-welllane.
After starting the reaction for each lane on the plate, the reaction
mixture was immediately loaded on a SpectraMax M5 (Molecular
Devices) where fluorescence was quantified over the course of
30 min at an excitation wavelength of 355 nm and an emission
wavelength of 460 nm. Single time points were chosen where the
positive control produced a fluorescence signal of approximately
1,000. All assays were done in triplicates and IC50 values for each
inhibitor were calculated with sigmoidal fitting of the log[inhibitor]
vs. inhibition percentage using GraphPad Prism.
Crystallization and drug soaking
NA crystals were grown using the hanging-drop vapor diffusion
method. Initial screening was performed using a commercial kit
(Hampton Research). Diffraction quality crystals of p57N2 were
obtained by mixing 1 uL of the concentrated protein at 10 mg/mL
in 20 mM Tris, pH 8.0, and 50 mM NaCl with 0.1M BIS-TRIS
propane (pH 9.0), 10% v/v Jeffamine ED-2001 (pH 7.0). N5
crystals were obtained using 0.1 M HEPES (pH 7.5), 12% w/v
polyethyleneglycol3,350at18uC[15].Qualityp09N1crystalswere
obtained as described previously using 0.16 M calcium acetate
hydrate, 0.08 M sodium cacodylate trihydrate, pH 6.5, 14.4%
polyethylene glycol 8000, 20% glycerol at 18uC [13]. NA protein
crystals were first incubated in mother liquor containing 20 mM of
inhibitor, and then flash-cooled at 100 K. Diffraction data for the
p57N2 and N5 were collected at KEK beamline Ne3A, while
p09N1 data were collected at SSRF beamline BL17U.
Data collection, processing and structure solution
Diffraction data were processed and scaled using HKL2000
[55]. Data collection and processing statistics are summarized in
Table 3. The structure of p57N2 was solved by molecular
replacement method using Phaser [56] from the CCP4 program
suite [57] with the structure of A/TOKYO/3/1967 H2N2 N2
(PDB code: 1IVG) as the search model [41]. Initial restrained
rigid-body refinement and manual model building were performed
using REFMAC5 [58] and COOT [59], respectively. Further
rounds of refinement were performed using the phenix.refine
program implemented in the PHENIX package with coordinate
refinement, isotropic ADP refinement and bulk solvent modeling
[60]. The stereochemical quality of the final model was assessed
with the program PROCHECK [61]. The final models have 84%
of the residues in the most favored region of the Ramachandran
plot [62] and no residue in disallowed regions. Structures of
p09N1 and N5 were solved as described previously [13,15].
PDB accession codes
All crystal structures have been deposited into the Protein Data
Bank (PDB, www.pdb.org) with the following PDB codes: N5-
laninamivir - 3TI8, p09N1-zanamivir - 3TI5, p09N1-laninamivir -
3TI3, p09N1-laninamivir octanoate - 3TI4, p09N1-oseltamivir -
3TI6, p57N2-zanamivir - 3TIC, p57N2-laninamivir - 3TIA, and
p57N2-laninamivir octanoate - 3TIB.
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